285 related articles for article (PubMed ID: 19713709)
1. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide.
Kwekkeboom DJ; Krenning EP; Scheidhauer K; Lewington V; Lebtahi R; Grossman A; Vitek P; Sundin A; Plöckinger U; ;
Neuroendocrinology; 2009; 90(2):184-9. PubMed ID: 19713709
[No Abstract] [Full Text] [Related]
2. Procedure guideline for somatostatin receptor scintigraphy with (111)In-pentetreotide.
Balon HR; Goldsmith SJ; Siegel BA; Silberstein EB; Krenning EP; Lang O; Donohoe KJ;
J Nucl Med; 2001 Jul; 42(7):1134-8. PubMed ID: 11438641
[No Abstract] [Full Text] [Related]
3. Somatostatin receptor imaging with (111)In-pentetreotide in gastro-intestinal tract and lung neuroendocrine tumors-Impact on targeted treatment.
Gerasimou G; Moralidis E; Gotzamani-Psarrakou A
Hell J Nucl Med; 2010; 13(2):158-62. PubMed ID: 20808990
[TBL] [Abstract][Full Text] [Related]
4. [Somatostatin receptor scintigraphy].
Rasmussen K; Nielsen JT; Rehling M
Ugeskr Laeger; 2005 Dec; 167(49):4647-50. PubMed ID: 16336855
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management.
Jamar F; Fiasse R; Leners N; Pauwels S
J Nucl Med; 1995 Apr; 36(4):542-9. PubMed ID: 7699439
[TBL] [Abstract][Full Text] [Related]
6. MIBG and radiolabeled octreotide in neuroendocrine tumors.
Hoefnagel CA
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):137-9. PubMed ID: 9002773
[TBL] [Abstract][Full Text] [Related]
7. The SNM practice guideline for somatostatin receptor scintigraphy 2.0.
Balon HR; Brown TL; Goldsmith SJ; Silberstein EB; Krenning EP; Lang O; Dillehay G; Tarrance J; Johnson M; Stabin MG;
J Nucl Med Technol; 2011 Dec; 39(4):317-24. PubMed ID: 22068564
[No Abstract] [Full Text] [Related]
8. 111Indium pentetreotide imaging in the evaluation of head and neck tumors.
Myssiorek D; Tronco G
Laryngoscope; 2005 Oct; 115(10):1707-16. PubMed ID: 16222183
[TBL] [Abstract][Full Text] [Related]
9. Somatostatin-receptor imaging of human malignancies: a new era in the localization, staging, and treatment of tumors.
Kvols LK
Gastroenterology; 1993 Dec; 105(6):1909-11. PubMed ID: 7902824
[No Abstract] [Full Text] [Related]
10. Metabolic and receptor imaging in patients with neuroendocrine tumors: comparison of fludeoxyglucose-positron emission tomography and computed tomography with indium in 111 pentetreotide.
Zalom ML; Waxman AD; Yu R; Lee J; Ih G; Wolin EM
Endocr Pract; 2009; 15(6):521-7. PubMed ID: 19491080
[TBL] [Abstract][Full Text] [Related]
11. [111In-pentetreotide in the study of tumors expressing somatostatin receptors].
Mateos Fernández J; Pons Pons F; Fuster Pelfort D; Vidal-Sicart S; Lomeña Caballero F; Herranz García-Romero R
Rev Esp Med Nucl; 1999 Oct; 18(5):325-30. PubMed ID: 10562660
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin-receptor imaging of neuroendocrine gastroenteropancreatic tumors.
Scherübl H; Bäder M; Fett U; Hamm B; Schmidt-Gayk H; Koppenhagen K; Dop FJ; Riecken EO; Wiedenmann B
Gastroenterology; 1993 Dec; 105(6):1705-9. PubMed ID: 7902821
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin Receptor Scintigraphy: Blazing in Indium and Quenching in Gallium.
Bodei L
J Nucl Med; 2020 Dec; 61(Suppl 2):121S-122S. PubMed ID: 33293432
[No Abstract] [Full Text] [Related]
14. Somatostatin receptor imaging, therapy and new strategies in patients with neuroendocrine tumours.
Slooter GD; Mearadji A; Breeman WA; Marquet RL; de Jong M; Krenning EP; van Eijck CH
Br J Surg; 2001 Jan; 88(1):31-40. PubMed ID: 11136306
[TBL] [Abstract][Full Text] [Related]
15. Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan).
Olsen JO; Pozderac RV; Hinkle G; Hill T; O'Dorisio TM; Schirmer WJ; Ellison EC; O'Dorisio MS
Semin Nucl Med; 1995 Jul; 25(3):251-61. PubMed ID: 7570044
[TBL] [Abstract][Full Text] [Related]
16. Preferential localization of regional metastases from gastroenteropancreatic endocrine tumors with somatostatin-receptor scintigraphy.
MacGillivray DC; Mumtaz MA; Kurtzman SH; Spencer RP; Weiner RE; Malchoff CD
Arch Surg; 1996 Dec; 131(12):1338-42. PubMed ID: 8956777
[TBL] [Abstract][Full Text] [Related]
17. Radiolabeled somatostatin analogs in the diagnosis and staging of neuroendocrine tumors.
Camera L; Del Vecchio S; Quarantelli M; Ibello F; Pellegrino T; Salvatore M
J Endocrinol Invest; 2003; 26(8 Suppl):60-2. PubMed ID: 15233215
[No Abstract] [Full Text] [Related]
18. Radiolabeled somatostaitin analogs in the treatment of neuroendocrine tumors: experience of the National Cancer Institute of Milano using high dose of 111In-pentetreotide in metastatic neuroendocrine gastroenteropancreatic tumors.
Bombardieri E; Seregni E; Savelli G; Villano C; Castellani MR; Cirillo F; Pallotti F; Fracassi S; Chiesa C; Chiti A; Bajetta E
J Endocrinol Invest; 2003; 26(8 Suppl):63-9. PubMed ID: 15233216
[No Abstract] [Full Text] [Related]
19. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives.
Breeman WA; de Jong M; Kwekkeboom DJ; Valkema R; Bakker WH; Kooij PP; Visser TJ; Krenning EP
Eur J Nucl Med; 2001 Sep; 28(9):1421-9. PubMed ID: 11585303
[TBL] [Abstract][Full Text] [Related]
20. Results and potential of somatostatin receptor imaging in gastroenteropancreatic tract tumours.
Chiti A; Briganti V; Fanti S; Monetti N; Masi R; Bombardieri E
Q J Nucl Med; 2000 Mar; 44(1):42-9. PubMed ID: 10932600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
